Join
Live feed
·
PRReleasevia Quantisnow
Psyence Biomedical Ltd. logo

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

ByQuantisnow·Wall Street's wire, on your screen.
PBM· Psyence Biomedical Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PBM (Psyence Biomedical Ltd.) and more on Quantisnow.